Recovery from the pandemic has been aided by rapid, low-cost, decentralized sample-to-answer diagnostics that are changing the future of healthcare. The global microfluidic devices market is predicted to reach USD 34.5 billion by 2028.
SCHOTT MINIFAB, a wholly owned subsidiary of SCHOTT AG, has announced enhanced service offerings and the opening of a new manufacturing facility at the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo. The facility will open this fall in Phoenix, Arizona, USA, offering diagnostic and life sciences companies an end-to-end solution to design, develop, manufacture and scale-up their consumable devices.
SCHOTT MINIFAB’s ability to produce high-quality glass and polymer substrates and integrated cartridges has made it an industry leader. SCHOTT acquired Applied Microarrays Inc. in October 2021 and has since integrated AMI’s best-in-class high-density array printing capabilities into a new unified service offering.
“The facility will play an important role in our unique service offerings and provides companies a partner to advance the manufacturing of consumable devices, empowering patients and providers to get diagnoses quicker and more accurately,” said Greg Wolters, CEO of SCHOTT MINIFAB. “Rather than managing dozens of suppliers, companies can partner with SCHOTT MINIFAB to handle the complete life-cycle of product development under one roof so they can focus their efforts on innovation and reduce the total cost of goods.”
The purpose-built facility further enhances SCHOTT MINIFAB’s service offerings and significantly increases SCHOTT’s manufacturing capabilities in the United States to serve its global customer base.